Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Williams-Sonoma, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Williams-Sonoma, Inc. trades at $221.79 (market cap $26.11B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays a 1.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WSM | |
|---|---|---|
Market Cap | $39.89B | $26.11B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $240.06 |
52-Week Low | $278.09 | $163.62 |
Enterprise Value | $38.15B | $26.95B |
Dividend Yield | — | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Williams-Sonoma (WSM) trades at $221.75, up 0.9% with a bullish technical signal. The company demonstrates strong profitability with 46.1% gross margins and 54% ROE, though revenue has declined from $8.7B in 2023 to $7.7B in 2025. Recent quarterly earnings have consistently beaten expectations, and the company maintains a $0.76 quarterly dividend. Analyst consensus is mixed with 29% buy ratings but a $215.50 price target below current levels.
WSM faces headwinds from revenue contraction and competitive pressures in home furnishings, though strong margins and consistent earnings beats provide support. The stock trades at premium valuations (P/E 24.9, P/S 3.4) requiring sustained execution. Near-term direction hinges on Q2 2026 earnings due next, with technical support at $217 and resistance at $223.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
